دورية أكاديمية
أعرض في EDS

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.

التفاصيل البيبلوغرافية
العنوان: Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
المؤلفون: Springuel L; Celyad SA, Mont-Saint-Guibert, Belgium., Lonez C; Celyad SA, Mont-Saint-Guibert, Belgium., Alexandre B; Celyad SA, Mont-Saint-Guibert, Belgium., Van Cutsem E; University Hospitals Leuven and KU Leuven, Leuven, Belgium., Machiels JH; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium., Van Den Eynde M; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium., Prenen H; University Hospital Antwerp (UZ Antwerp), Antwerp, Belgium., Hendlisz A; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Shaza L; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Carrasco J; Grand Hôpital de Charleroi (GHdC), Charleroi, Belgium., Canon JL; Grand Hôpital de Charleroi (GHdC), Charleroi, Belgium., Opyrchal M; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Odunsi K; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Rottey S; Ghent University Hospital, Ghent, Belgium., Gilham DE; Celyad SA, Mont-Saint-Guibert, Belgium., Flament A; Celyad SA, Mont-Saint-Guibert, Belgium., Lehmann FF; Celyad SA, Mont-Saint-Guibert, Belgium. flehmann@celyad.com.
المصدر: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2019 Oct; Vol. 33 (5), pp. 515-537.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9705305 Publication Model: Print Cited Medium: Internet ISSN: 1179-190X (Electronic) Linking ISSN: 11738804 NLM ISO Abbreviation: BioDrugs Subsets: MEDLINE
أسماء مطبوعة: Publication: Auckland : Adis, Springer International
Original Publication: Mairangi Bay, Auckland, N.Z. ; Langhorn, PA : Adis International, c1997-
مواضيع طبية MeSH: Cell- and Tissue-Based Therapy/*methods , Neoplasms/*therapy , Receptors, Chimeric Antigen/*therapeutic use , Tumor Microenvironment/*immunology, Animals ; Cell- and Tissue-Based Therapy/adverse effects ; Clinical Trials as Topic ; Humans ; Neoplasms/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/transplantation
مستخلص: Chimeric antigen receptor-T cells (CAR-Ts) are an exciting new cancer treatment modality exemplified by the recent regulatory approval of two CD19-targeted CAR-T therapies for certain B cell malignancies. However, this success in the hematological setting has yet to translate to a significant level of objective clinical responses in the solid tumor setting. The reason for this lack of translation undoubtedly lies in the substantial challenges raised by solid tumors to all therapies, including CAR-T, that differ from B cell malignancies. For instance, intravenously infused CAR-Ts are likely to make rapid contact with cancerous B cells since both tend to reside in the same vascular compartments within the body. By contrast, solid cancers tend to form discrete tumor masses with an immune-suppressive tumor microenvironment composed of tumor cells and non-tumor stromal cells served by abnormal vasculature that restricts lymphocyte infiltration and suppresses immune function, expansion, and persistence. Moreover, the paucity of uniquely and homogeneously expressed tumor antigens and inherent plasticity of cancer cells provide major challenges to the specificity, potency, and overall effectiveness of CAR-T therapies. This review focuses on the major preclinical and clinical strategies currently being pursued to tackle these challenges in order to drive the success of CAR-T therapy against solid tumors.
References: Immunotherapy. 2017 Aug;9(9):723-733. (PMID: 28771104)
Mol Ther. 2010 Apr;18(4):843-51. (PMID: 20179677)
Clin Cancer Res. 2015 May 15;21(10):2278-88. (PMID: 25695689)
Nat Biomed Eng. 2018 Jun;2(6):377-391. (PMID: 31011197)
N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370)
Clin Cancer Res. 2012 Dec 1;18(23):6436-45. (PMID: 23032741)
Cancer Immunol Res. 2018 Sep;6(9):1100-1109. (PMID: 30030295)
Cancer Immunol Res. 2016 Aug;4(8):658-68. (PMID: 27329987)
JAMA Oncol. 2017 Aug 01;3(8):1094-1101. (PMID: 28426845)
Clin Cancer Res. 2018 Mar 15;24(6):1277-1286. (PMID: 29138340)
Nat Rev Cancer. 2016 May;16(5):275-87. (PMID: 27079802)
Sci Transl Med. 2014 Feb 19;6(224):224ra25. (PMID: 24553386)
N Engl J Med. 2011 Aug 25;365(8):725-33. (PMID: 21830940)
Cancer Gene Ther. 2020 May;27(5):341-355. (PMID: 31155611)
Curr Opin Immunol. 2015 Apr;33:9-15. (PMID: 25621840)
N Engl J Med. 2016 Dec 29;375(26):2561-9. (PMID: 28029927)
Front Immunol. 2018 Dec 03;9:2740. (PMID: 30559740)
Blood. 1997 Oct 1;90(7):2541-8. (PMID: 9326219)
Nat Med. 2008 Nov;14(11):1264-70. (PMID: 18978797)
Cancer Immunol Res. 2013 Jul;1(1):43-53. (PMID: 24409448)
Dis Markers. 2019 Feb 11;2019:3425291. (PMID: 30886654)
Front Immunol. 2018 Jul 27;9:1740. (PMID: 30140266)
Nat Nanotechnol. 2017 Aug;12(8):813-820. (PMID: 28416815)
N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870)
Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42. (PMID: 24099518)
Trends Mol Med. 2017 May;23(5):430-450. (PMID: 28416139)
Cancer Immunol Res. 2014 Feb;2(2):154-66. (PMID: 24778279)
Cancer Res. 2012 Apr 1;72(7):1844-52. (PMID: 22315351)
Nat Biotechnol. 2018 Oct;36(9):847-856. (PMID: 30102295)
Mol Ther. 2017 Jan 4;25(1):249-258. (PMID: 28129119)
Cancer Immunol Immunother. 2007 Dec;56(12):1875-83. (PMID: 17479266)
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8. (PMID: 2513569)
Sci Transl Med. 2013 Mar 20;5(177):177ra38. (PMID: 23515080)
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7624-7631. (PMID: 30936321)
J Clin Invest. 2019 Feb 25;129(4):1551-1565. (PMID: 30694219)
Cancer Res. 2016 Mar 15;76(6):1578-90. (PMID: 26979791)
Oncoimmunology. 2015 Jan 23;4(3):e994446. (PMID: 25949921)
Sci Transl Med. 2014 Nov 5;6(261):261ra151. (PMID: 25378643)
Cell Rep. 2017 Dec 12;21(11):3205-3219. (PMID: 29241547)
Blood. 2013 Jan 24;121(4):573-84. (PMID: 23160470)
Curr Hematol Malig Rep. 2018 Dec;13(6):534-542. (PMID: 30362020)
Blood. 2005 Jun 1;105(11):4247-54. (PMID: 15728125)
Am J Transl Res. 2015 Mar 15;7(3):460-73. (PMID: 26045887)
Sci China Life Sci. 2016 May;59(5):468-79. (PMID: 26968708)
Clin Cancer Res. 2015 Jul 15;21(14):3149-59. (PMID: 25850950)
Cancer Immunol Res. 2018 Jul;6(7):812-824. (PMID: 29720380)
Cancer Gene Ther. 2016 May;23(5):142-8. (PMID: 27080226)
PLoS One. 2015 Jun 01;10(6):e0128151. (PMID: 26030772)
J Clin Invest. 2016 Aug 1;126(8):3130-44. (PMID: 27454297)
J Clin Oncol. 2015 Feb 20;33(6):540-9. (PMID: 25154820)
Blood. 2011 Dec 1;118(23):6050-6. (PMID: 21984804)
Nat Biotechnol. 2013 Jan;31(1):71-5. (PMID: 23242161)
BMJ Open. 2017 Nov 12;7(11):e017075. (PMID: 29133316)
Cancer Res. 2013 Sep 1;73(17):5315-9. (PMID: 23733750)
Future Sci OA. 2017 Dec 07;4(3):FSO271. (PMID: 29568561)
Int Immunopharmacol. 2019 May;70:498-503. (PMID: 30875561)
Clin Cancer Res. 2013 Oct 15;19(20):5636-46. (PMID: 23873688)
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8. (PMID: 26759368)
J Immunother. 2010 Oct;33(8):780-8. (PMID: 20842059)
Mol Ther. 2014 Jun;22(6):1211-1220. (PMID: 24732709)
Blood. 2014 Jun 12;123(24):3750-9. (PMID: 24782509)
Mol Ther. 2018 Jul 5;26(7):1855-1866. (PMID: 29807781)
J Clin Immunol. 2011 Aug;31(4):710-8. (PMID: 21505816)
Oncoimmunology. 2014 Dec 21;3(11):e970027. (PMID: 25941599)
Nat Med. 2018 May;24(5):563-571. (PMID: 29713085)
Cancers (Basel). 2017 Jul 18;9(7):. (PMID: 28718815)
Cancer Cell. 2015 Nov 9;28(5):638-652. (PMID: 26525103)
Nat Med. 2011 Sep 18;17(10):1290-7. (PMID: 21926977)
Sci Rep. 2017 Sep 5;7(1):10541. (PMID: 28874817)
Sci Rep. 2017 Apr 7;7(1):737. (PMID: 28389661)
Br J Cancer. 2019 Jan;120(1):26-37. (PMID: 30413825)
Sci Transl Med. 2013 Dec 11;5(215):215ra172. (PMID: 24337479)
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E459-68. (PMID: 26759369)
Curr Res Transl Med. 2018 May;66(2):53-56. (PMID: 29625833)
Nat Med. 2019 Jan;25(1):82-88. (PMID: 30559421)
Blood Cancer J. 2016 Aug 12;6(8):e458. (PMID: 27518241)
Am J Hematol. 2019 May;94(S1):S34-S41. (PMID: 30632631)
Cancer Cell. 2015 Oct 12;28(4):415-428. (PMID: 26461090)
Mol Ther. 2007 Apr;15(4):825-33. (PMID: 17299405)
Clin Cancer Res. 2015 Sep 15;21(18):4062-72. (PMID: 26059190)
Oncotarget. 2018 Nov 9;9(88):35807-35808. (PMID: 30533195)
J Clin Oncol. 2015 May 20;33(15):1688-96. (PMID: 25800760)
Blood. 2013 Aug 22;122(8):1341-9. (PMID: 23741009)
Immunol Rev. 2014 Jan;257(1):83-90. (PMID: 24329791)
J Clin Invest. 2016 Nov 1;126(11):4262-4272. (PMID: 27760047)
Cancer Cell. 2017 Mar 13;31(3):311-325. (PMID: 28292435)
Blood. 2009 Jun 18;113(25):6392-402. (PMID: 19377047)
Blood. 2012 Jun 14;119(24):5697-705. (PMID: 22535661)
Cancer Res. 2011 Sep 1;71(17):5697-706. (PMID: 21742772)
Cell Rep. 2017 Sep 26;20(13):3025-3033. (PMID: 28954221)
Future Oncol. 2017 Aug;13(18):1593-1605. (PMID: 28613086)
Cancer Immunol Res. 2015 Apr;3(4):368-79. (PMID: 25576337)
Cancer Lett. 2017 May 1;393:52-59. (PMID: 28223167)
Clin Cancer Res. 2014 Aug 15;20(16):4262-73. (PMID: 24919573)
Cancer Discov. 2013 Apr;3(4):388-98. (PMID: 23550147)
Front Immunol. 2019 Jan 11;9:3084. (PMID: 30687313)
N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
Blood. 2011 Jan 6;117(1):72-82. (PMID: 20889925)
Cell. 2018 May 31;173(6):1426-1438.e11. (PMID: 29706540)
Methods Mol Biol. 2015;1317:365-82. (PMID: 26072418)
Mol Med. 2012 May 09;18:565-76. (PMID: 22354215)
Cancers (Basel). 2018 Dec 28;11(1):. (PMID: 30597841)
Cancer Immunol Res. 2014 Feb;2(2):112-20. (PMID: 24579088)
Blood. 2014 Aug 21;124(8):1277-87. (PMID: 24970931)
Front Oncol. 2017 Jan 31;7:3. (PMID: 28197395)
Immunotherapy. 2015;7(3):229-41. (PMID: 25804476)
Clin Cancer Res. 2008 Jun 1;14(11):3462-9. (PMID: 18519778)
J Immunol. 2009 Dec 1;183(11):6939-47. (PMID: 19915047)
J Immunol. 2013 Mar 1;190(5):2455-63. (PMID: 23355740)
معلومات مُعتمدة: P50 CA159981 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Receptors, Chimeric Antigen)
تواريخ الأحداث: Date Created: 20190801 Date Completed: 20200217 Latest Revision: 20240720
رمز التحديث: 20240720
مُعرف محوري في PubMed: PMC6790340
DOI: 10.1007/s40259-019-00368-z
PMID: 31363930
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-190X
DOI:10.1007/s40259-019-00368-z